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Finishing Strong
W
hile writing my last editorial for
Diabetes Care ﬁlls me with a
sense of accomplishment, more
importantlyIcannothelpbutfeelgrateful
for the opportunity and the honor of be-
ingassociatedwiththejournalatatimeof
its tremendous growth and success.
In the last 5 to 10 years, Diabetes Care
has continuously grown in terms of the
submission numbers (over 11,500 new
articles in 4 years!), impact factor, and
readership. It is well established as the
leading diabetes clinical journal world-
wide and is now published in several lan-
guages.OurWebsitecontinuestobevery
popular as judged by the large number of
daily “hits.” We continue to take pride in
the fact that the journal, along with the
American Diabetes Association, remains
themajorsourceofinformationaboutthe
diseaseinternationally.Mostimportantly,
I have learned a tremendous amount
about diabetes from our authors and re-
viewers, as well as about the publishing
process,whichcontinuestoevolveasnew
technologies become available.
I look forward to handing over the
expectation that Diabetes Care will con-
tinuetoinnovateandachievenewsuccess
as the premier journal in diabetes to the
incoming team. This comes at a time of
considerable challenges with ﬁnancial
andotherobstaclesrestrictingprogressin
research to ﬁnd a cure and improve the
lives for people with diabetes. Despite
these obstacles and diminished research
funding,wecontinuetoattracthighqual-
ity research covering all clinical aspects of
the disease from epidemiology to every-
day clinical care. Our submission rate
continues to grow, which brings a down-
side—the rise in our rejection rate—now
over 80%.
To help us produce an outstanding
journal we need your help, and I must
once again make the appeal for reviewers,
pointing out that it is the responsibility of
all authors, and indeed all readers, of the
journal. It is a privilege to serve as a re-
viewer, and by critiquing articles in a
timely way you are sharing your experi-
ence with the Editorial Committee and
authors to assure that the highest quality
papers are published in a timely manner.
We do have many outstanding reviewers
and are very grateful to them for their
dedication to the journal. However, only
1,294 out of 6,745 eligible reviewers
agreed to review. Those that review fre-
quently and qualify for the Star Rewards
program are sent a small token of appre-
ciation at the end of each year. I take this
opportunity to thank all of our reviewers,
but in particular Professor Harry Keen,
one of our best, who has received a letter
(andaDiabetesCarecoffeemug!)10years
in a row.
Wecontinuetotakeprideintherapid
turnaround of our review and decision
process, our average time to ﬁrst decision
being slightly over 18 days. We have also
been able to minimize paper consump-
tion by qualifying a signiﬁcant amount of
material as online-publication only. In
addition,itwillsoonbepossibletodown-
load this material when the main article is
downloaded from the Web site, allowing
readers to view the paper in its entirety.
We have also invested in software to rec-
ognize and minimize plagiarism, which is
fortunately rare but must be detected and
dealt with.
Wehavemadeeveryefforttobemore
transparentinhavingauthorsandreview-
ers declare conﬂicts of interest, and we
will continue to take steps to minimize
these. On the other hand, we must not
shut the door to collaborations with in-
dustry and other partners who persevere
in their efforts to ﬁnd a cure for diabetes–
whether altruistic or for proﬁt.
We continue to make progress in our
technologies that make our information
available in formats that are more accept-
able to a greater variety of people. We
have recently begun developing brief pod
casts, which consists of a discussion be-
tween the editor and author summarizing
the research and giving our audience a
succinct insight into the thought process
behind that particular article, as well as
futureresearch.Theseareavailableonour
Web site and through Diabetes Digest.
These are challenging times in health
care and chronic disease, and we have
highlighted the issues facing us in deliv-
ering care with commentaries on health
care reform and trends in delivering cost-
effective care. We look forward to pub-
lishing papers that demonstrate
innovations in technology and medica-
tions that will improve the lives of people
with diabetes as we establish these new
systems of care.
I would like to thank our outstanding
team of associate editors and the Editorial
Board,particularlythosewhoarerotating
off of the board: Dorothy Becker, Nichola
Davis, Richard Grant, Margaret Gray, Sil-
vio Inzucchi, Laurence Kennedy, Law-
rence Perlmuter, Matthew Riddle, Sharon
Saydah, Guillermo Umpierrez, and
Rachel Wildman and welcome new Edi-
torialBoardmemberswhohavebeenout-
standingreviewersoverthelastfewyears.
None of our success would have been
possible without the hard work and orga-
nization in our editorial ofﬁce, which for
several years has remained in Indianapo-
lis, and in particular Lyn Reynolds, Shan-
non Potts, Jane Lucas, Rita Summers, and
Joan Garrett, as well as the publishing
team in our Alexandria ofﬁce. I look for-
ward to continuing to work with them—
even though it will not be as editor after
2011.
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